Figure 1 - uploaded by Theodor Voiosu
Content may be subject to copyright.
Source publication
Gastrointestinal stromal tumors (GISTs) have been a topic of increasing interest since the discovery of their cellular activation pathway via the receptor for tyrosine kinase (KIT) leading to the possibility of targeted molecular therapy in the form of imatinib mesylate. Endoscopic diagnostic and therapeutic possibilities have also been developing...
Context in source publication
Context 1
... EUS, most GISTs present as hypoechoic masses arising from the second or the fourth layer of the GI tract, corresponding to the muscularis mucosae and the muscularis propria [7]. Tumor origin is usually in the 4 th layer and only rarely do GIST originate in the 2 nd layer (Figures 1, 2). ...
Similar publications
Gastrointestinal stromal tumors (GIST) rarely affect pediatric and adolescent patients. Herein, we report the case of a 27-year-old woman who was referred to our hospital for a detailed examination of an intra-abdominal tumor and ascites. Upper gastrointestinal endoscopy and contrast-enhanced abdominal CT revealed a ruptured large submucosal tumor...
Molecular-targeting therapy using tyrosine kinase inhibitor imatinib mesylate is effective for metastasis/recurrent gastrointestinal stromal tumors (GISTs). Likewise, imatinib would be effective in the neoadjuvant therapy for high-risk GIST. Neoadjuvant therapy may have the potential to increase the complete resection rate and to avoid the surgical...
A 13-year-old spayed mixed-breed dog was diagnosed with a gastrointestinal
stromal tumor (GIST) after histopathological examination of an abdominal mass. Five months
after surgical resection of the tumor, we detected the recurrence of GIST with multiple
disseminated abdominal lesions. A sequence analysis of cDNA obtained from a biopsy of the
recurr...
Citations
... Следует отметить, что чаще всего не удавалось получить материал для морфологического исследования при субэпителиальных образованиях, хотя именно у этих пациентов предпочитали использовать иглы максимального диаметра, в том числе типа ProCore с режущей выемкой, полагая, что это будет способствовать повышению эффективности пункции. Наши результаты подтверждаются и данными литературы [4,5,6,7]. До сих пор вопрос о необходимости выполнения ЭУС-ТИП субэпителиальных образований остается дискутабельным, хотя с онкологических позиций все же рекомендуется получение материала для верификации диагноза, исключение составляют образования размером до 1 см, которые можно удалить эндоскопическими методами [8]. Описано, что ЭУС-ТИП с использованием игл ProCore 20G эффективна для гистопатологической верификации субэпителиальных образований ЖКТ с меньшим количеством проходов, чем стандартные аспирационные иглы [9]. ...
Gastrointestinal stromal tumors (GISTs) are rare malignancies that are mesenchymal in origin. While surgery continues to be the gold standard for primary, resectable disease, the advent of tyrosine kinase inhibitors has dramatically changed the management of metastatic disease as well as the pre- and postoperative treatment paradigms for primary disease. Specifically, the tyrosine kinase inhibitors imatinib, sunitinib, and regorafenib are now employed as first-, second-, and third-line therapy for metastatic GIST. Imatinib is also used in the neoadjuvant and adjuvant setting for patients with primary GIST.
Advances in endoscopic imaging technology have led to the detection of more cases of gastrointestinal submucosal lesions (SMLs). Endoscopic ultrasonography (EUS) was previously known as the best imaging procedure to characterize SMLs. However, the progress of endoscopic submucosal dissection (ESD) has raised some new questions concerning the role of EUS in the diagnosis of SMLs. What is the diagnostic accuracy of EUS for SMLs? How is the nature of SMLs determined? How is the layer of origin identified? What is the preoperative value of EUS for ESD? In this review, we will discuss the endosonographic features of SMLs, the diagnostic accuracy of EUS, the ability of EUS to distinguish benign and malignant SMLs, the value of EUS-guided fine-needle aspiration (FNA), and the value of EUS in clinical surveillance. © 2013 Baishideng Publishing Group Co., Limited. All rights reserved.
